Android app on Google Play

BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q4 Loss of 22c/Share

February 19, 2013 6:14 AM EST Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.22), $0.06 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.02 million.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.




You May Also Be Interested In


Related Categories

Earnings

Related Entities

Earnings

Add Your Comment